Table 3.
Oncological outcomes
| Salvage subtypes |
Salvage total | Primary total | p value | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Whole gland | Matched primary | p value | Focal gland | Matched primary | p value | Whole/focal p value | ||||
| Follow-up (d0, median (IQR) | 490 (261, 1053) | 530 (328, 841) | 0.702 | 541.5 (312, 890) | 649 (401, 1109) | 0.096 | 0.669 | 521 (304, 951) | 638 (394, 951) | 0.245 |
| Surgical margins, n (%) | ||||||||||
| Negative | 32 (65.3) | 39 (79.6) | 0.087 | 52 (60.5) | 64 (74.4) | 0.117 | 0.787 | 84 (62.2) | 103 (76.3) | 0.022 |
| Positive <3 mm | 8 (16.3) | 7 (14.3) | 22 (25.6) | 13 (15.1) | 30 (22.2) | 20 (14.8) | ||||
| Positive >3 mm | 9 (18.4) | 3 (6.1) | 12 (14.0) | 9 (10.5) | 21 (15.6) | 12 (8.9) | ||||
| T stage postop, n (%) | ||||||||||
| T1 | 0 | 0 | 0.317 | 0 | 0 | 0.467 | 0.069 | 0 | 0 | 0.339 |
| T2 | 16 (32.7) | 21 (42.9) | 42 (48.8) | 45 (52.3) | 58 (43.0) | 66 (48.9) | ||||
| T3 | 33 (67.3) | 28 (57.1) | 44 (51.2) | 41 (47.7) | 77 (57.0) | 69 (51.1) | ||||
| Upstaging, n (%) | 20 (40.8) | 17 (34.7) | 0.678 | 40 (46.5) | 31 (36.0) | 0.253 | 0.522 | 60 (44.4) | 48 (35.6) | 0.195 |
| Gleason postop, n (%) | ||||||||||
| 3 + 3 | 0 | 1 (2.0) | 0.467 | 1 (1.2) | 3 (3.5) | 0.427 | 0.016 | 1 (0.7) | 4 (3.0) | 0.288 |
| 3 + 4 | 17 (34.7) | 17 (34.7) | 46 (53.5) | 44 (51.2) | 63 (46.7) | 61 (45.2) | ||||
| 3 + 5 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| 4 + 3 | 19 (38.8) | 14 (28.6) | 26 (30.2) | 18 (20.9) | 45 (33.3) | 32 (23.7) | ||||
| 4 + 4 | 3 (6.1) | 1 (2.0) | 5 (5.8) | 7 (8.1) | 8 (5.9) | 8 (5.9) | ||||
| 4 + 5 | 10 (20.4) | 13 (26.5) | 8 (9.3) | 12 (14.0) | 18 (13.3) | 25 (18.5) | ||||
| 5 + 4 | 0 | 3 (6.1) | 0 | 2 (2.3) | 0 | 5 (3.7) | ||||
| Upgrading, n (%) | 15 (30.6) | 13 (26.5) | 0.839 | 14 (16.3) | 13 (15.1) | >0.999 | 0.051 | 29 (21.5) | 26 (19.3) | 0.779 |
| Total recurrence, n (%) | 18 (36.7) | 6 (12.2) | 0.004 | 25 (29.1) | 13 (15.1) | 0.059 | 0.687 | 43 (31.9) | 19 (14.1) | 0.001 |
| Biochemical only | 11 (22.4) | 4 (8.2) | 19 (22.1) | 9 (10.5) | 30 (22.2) | 13 (9.6) | ||||
| Lesion | 7 (14.3) | 2 (4.1) | 6 (7.0) | 4 (4.7) | 13 (9.6) | 6 (4.4) | ||||
| Further ADT, n (%) | 18 (36.7) | 7 (14.3) | 0.013 | 26 (30.2) | 14 (16.3) | 0.059 | 0.438 | 44 (32.6) | 21 (15.6) | 0.002 |
| Further radiotherapy, n (%) | 2 (4.1) | 0 | 0.500 | 11 (12.8) | 0 | 0.001 | 0.099 | 13 (9.6) | 0 | <0.001 |
| Further chemotherapy, n (%) | 1 (1.7) | 0 | >0.999 | 1 (1.2) | 0 | >0.999 | 0.685 | 2 (1.5) | 0 | 0.500 |
| Overall survival, n (%) | 44 (89.8) | 49 (100) | 0.063 | 85 (98.8) | 85 (98.8) | >0.999 | 0.014 | 129 (95.6) | 134 (99.3) | 0.125 |
ADT = androgen deprivation therapy; IQR = interquartile range.